Posted from: Tuesday, October 07, 2014 - 05:05 PM - Present

Ferric Citrate Approved for Dialysis Patients with High Blood Phosphate Levels

September 5, 2014 – The U.S. Food and Drug Administration (FDA) approved ferric citrate (also known as Zerenex) to treat hyperphosphatemia (high blood phosphate levels) which occurs in patients receiving dialysis for chronic kidney disease.  Ferric citrate is manufactured by Keryx Biopharmaceuticals.

Ferric citrate helps prevent the body from absorbing phosphate from foods because too much phosphate can accumulate in the blood which increases the risk for bone loss, cardiovascular disease and death. In addition, ferric citrate also increases blood iron supplies, which often are depleted by dialysis. Ferric citrate is to be taken as two tablets with each meal.

Keryx plans to give ferric citrate a brand name and to launch it by the end of 2014 and is anticipated to cost approximately $3,000 to $5,000 annually per patient.

 

If you have any questions you can contact our Client Services Call Center at 1-877-723-6005.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

 

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Tuesday, November 21, 2017 - 08:41 AM.